Faculty
Thomas W. Abrams, RPh, MBA, Director, Division of Drug Marketing, Advertising, and Communications (DDMAC), Office of Medical Policy (OMP), CDER, FDA
Minnie V. Baylor-Henry, JD, Vice President, Regulatory & Capital Markets Consulting, Deloitte & Touche LLP
Alan R. Bennett, Partner, Ropes & Gray, LLP
Sara M. Bloom, Assistant U.S. Attorney and Chief of Affirmative Litigation, District of Massachusetts, U.S. Attorney’s Office, U.S. Department of Justice
Nathan G. Cortez, Assistant Professor of Law, Dedman School of Law, Southern Methodist University
Allan Coukell, Director, The Pew Prescription Project, Pew Charitable Trusts
Kristin I. Davis, JD, Deputy Director, DDMAC, OMP, CDER, FDA
Robert T. Dean, Group Leader, Direct-to-Consumer Review Group I, DDMAC,
OMP, CDER, FDA
Mark A. DeWyngaert, PhD, Managing Director, Huron Consulting Group
Norman A. Drezin, RPh, JD, President, Drezin Consultants, LLC
Anne Edwards, Director of Customer Engagement, MCCann Healthcare Worldwide
Jeffrey K. Francer, Assistant General Counsel, PhRMA
Mary L. Gerdes, Senior Counsel, BD
Martine L. Hartogensis, DVM, Deputy Director, Office of Surveillance and Compliance, CVM, FDA
Elenita Y. Ibarra-Pratt, RN, MPH, Branch Chief, Advertising and Promotional Labeling Branch (APLB), Division of Case Management (DCM), Office of Compliance and Biologics Quality (OCBQ), CBER, FDA
Rady A. Johnson, Senior Vice President & Assistant General Counsel, Pfizer, Inc.
John F. Kamp, PhD, Executive Director, Coalition for Healthcare Communication, and, Of Counsel, Wiley Rein LLP
Coleen E. Klasmeier, Partner, Life Sciences Practice, Sidley Austin LLP
Michael K. Loucks, Acting U.S. Attorney, District of Massachusetts, U.S. Attorney’s Office, U.S. Department of Justice
Kendra A. Martello, Assistant General Counsel, PhRMA
Dorothy R. McAdams, VMD, Team Leader, Post-Approval Review Team, Division of Surveillance, Office of Surveillance and Compliance, CVM, FDA
Philomena McArthur, JD, Senior Director, Pharma Health Care Compliance Regulatory Advertising & Promotion, Johnson & Johnson Pharmaceutical Research & Development, LLCMichael McCaughan, Editor-In-Chief, FDC Windhover Biopharma Group
Michael A. Misocky, RPh, JD, President, Misocky Consulting Group, LLC
Diane Mitrione, Assistant Vice President, Global Regulatory Affairs, Wyeth Pharmaceuticals
Mary Jane Nehring, Executive Director, Global Regulatory Affairs,
Schering-Plough Corporation
Patrick C. O'Brien, PharmD, Attorney, Burke O'Neil LLC
Wayne L. Pines, President, Regulatory Services and Healthcare, APCO Worldwide
Mary E. Riordan, Senior Counsel, Administrative & Civil Remedies Branch, Office of the Inspector General, U.S. Department of Health & Human Services
Janet Lucy Rose, President, Lucy Rose Associates
Ellen S. Rosenberg, Vice President and Senior Counsel, Shire
Paul J. Savidge, JD, MBA, Vice President & Associate General Counsel,
Bristol-Myers Squibb
Marc J. Scheineson, Partner, Alston & Bird LLP
Lynn Shapiro Snyder, Senior Member, Epstein Becker & Green, P.C.
Lisa L. Stockbridge, PhD, Consumer Safety Officer, APLB, DCM, OCBQ, CBER, FDA
Helen W. Sullivan, PhD, MPH, Social Science Analyst, Direct-to-Consumer Review Group Research Team, DDMAC, OMP, CDER, FDA
Stephen D. Terman, Principal, Olsson Frank Weeda Terman Bode Matz PC
Martin Tiemann, DVM, Senior Associate Director, Regulatory Affairs Post Approval, Boehringer-Ingelheim Vetmedica, Inc.
Andrew Van Haute, Associate General Counsel, AdvaMed
Alexander C. Vandevere, Digital Strategy Leader, Global Prairie
Sangeeta Vaswani, PharmD, Group Leader, Direct-to-Consumer Review Group III, DDMAC, OMP, CDER, FDA
Deborah A. Wolf, JD, Supervisory Regulatory Counsel, Regulations Staff, Office of Communications, Education, and Radiation Programs, CDRH, FDA
Janet Woodcock, MD, Director, CDER, FDA